MPN_Hub

HCPs, the phase III SURPASS-ET trial demonstrated the efficacy of ropeginterferon alfa-2b (ropeg) as a second-line treatment for #EssentialThrombocythemia (ET). Of your patients with ET, what proportion are you currently treating with ropeg? #MPN #MPNsm #MedEd

New publication 📝 Preliminary results from the phase I INCA33989-101/102 trials presented at #EHA2025 by John Mascarenhas show INCA33989 was well tolerated with no DLTs and only one discontinuation in patients with CALR-mutated ET. Learn more: loom.ly/mb67VWI #MPN…

Did you know you can filter content on the #MPN Hub website depending on your specific interests – whether that is by MPN type, therapeutics, trials, or congresses? 👉 loom.ly/AQFU688 #mpnsm #MedEd

📝 A new phase II study presented at #EHA2025 by @HarryGillHKUMed found that ropeginterferon alfa-2b was well tolerated and showed sustained hematologic and molecular responses in early/lower-risk MF. More news: mpn-hub.com #MPN #myelofibrosis #MedNews #MedEd #MPNsm

New publication 📝 Phase II P1101MF results presented at #EHA2025 by @HarryGillHKUMed show ropeginterferon alfa-2b achieved a 63.5% hematologic response at Week 48 in early/lower-risk MF. Learn more: loom.ly/WR12HOI #MPN #myelofibrosis #MedNews #MedEd #MPNsm

📝 SANRECO phase I results presented at #EHA2025 by @MKremyanskaya show divesiran, a GalNAc–siRNA, increased hepcidin and ferritin levels, improving iron storage in patients with PV. More news: mpn-hub.com #PolycythemiaVera #MedNews #MedEd #MPN #MPNsm

New publication 📝 SANRECO phase I results presented by @MKremyanskaya at #EHA2025 show that divesiran reduced phlebotomy need and improved iron parameters in patients with PV. Learn more: loom.ly/grC6lN8 #PolycythemiaVera #MedNews #MedEd #MPN #MPNsm

📝 Long-term results from the MANIFEST-2 study presented by Alessandro Vannucchi at #EHA2025 found that Pela+Rux achieved higher TSS50 response rates (42.1% vs 35.2%) at Wk 72 compared with Pbo+Rux in patients with JAKi-naïve MF More news: mpn-hub.com #MPN #mpnsm…

New data 📝 Long-term results from the MANIFEST-2 study presented by Alessandro Vannucchi at #EHA2025 show sustained SVR35 responses at Wk 72 with Pela+Rux vs Pbo+Rux (46.3% vs 29.2%) in patients with JAKi-naïve MF Learn more: loom.ly/EUbQxKk #MPN #mpnsm #MedCongress…

📝 Updated results from the IMproveMF trial presented by John Mascarenhas at #ASCO2025 found that the pharmacokinetic profile of the imetelstat and ruxolitinib combination was similar to previously reported studies. More news: mpn-hub.com #MPN #mpnsm #MedCongress…

New data 📝 Updated results from the IMproveMF trial presented by John Mascarenhas at #ASCO2025 show no DLTs or Grade 5 TEAEs with imetelstat at any dose level in patients with int-1, int-2, or high-risk MF. Learn more: loom.ly/1FUxrPI #MPN #mpnsm #MedCongress #MedEd

📝 Results from the SURPASS-ET trial presented by Ruben Mesa at #ASCO2025 found that the incidence of major ET-related thrombotic (1.1% vs 10.0%) and cardiovascular (0% vs 7.5%) events were lower with ropeg vs anagrelide. More news: mpn-hub.com #MPN #mpnsm…

New data 📝 SURPASS-ET trial results presented by Ruben Mesa at #ASCO2025 show ropeg has superior efficacy vs anagrelide, with ELN modified response achieved by 42.9% vs 6.0% of patients with ET (p = 0.0001). Learn more: loom.ly/Ls3_iG8 #MPN #mpnsm #MedCongress #MedEd

📝Results from the phase III VERIFY trial presented by Andrew Kuykendall at #ASCO2025 found that rusfertide was associated with a lower mean phlebotomy rate vs placebo in patients with PV (0.5 vs 1.8; p < 0.0001). More news: mpn-hub.com #MPN #mpnsm #MedNews #MedEd

Thank you to our funders, who make it possible for us to deliver the #MPN Hub. • AOP Health • Bristol Myers Squibb • GSK • Incyte #MPNsm

New data 📝 Phase III VERIFY trial results presented by Andrew Kuykendall at #ASCO2025 show rusfertide achieved a higher response rate vs placebo in patients with PV (76.9% vs 32.9%; p < 0.0001). Learn more: loom.ly/zUWYo4w #MPN #mpnsm #MedNews #MedEd

📝A case series published in @BloodJournal found that assessment of symptoms, cardiovascular risk, mutations, leukocytosis, thrombocytosis, splenomegaly, and frequency of phlebotomy were indicators for cytoreductive treatment in low-risk PV. More news: mpn-hub.com…

During #EHA2025, Francesca Palandri highlighted the importance of anemia improvement for patients with #myelofibrosis and anemia, and the potential benefits of early intervention with momelotinib. Watch here: loom.ly/8FIOVOc #MPN #MPNsm #MedicalCongress

New publication 📝 A case series published in @BloodJournal recommends interferon alpha or hydroxyurea as first-line therapy in patients with low-risk PV. Learn more: loom.ly/p8C51Ks #MPN #mpnsm #MedNews #MedEd

During #EHA2025, Francesca Palandri discussed SVR35 and transfusion independence responses with momelotinib vs ruxolitinib in patients with MF and anemia, and the implications for OS. Watch here: loom.ly/u87xFdw #MPN #MPNsm #MedicalCongress